NEW YORK: Wall Street is holding its breath for the rekindling of mergers and acquisitions (M&As) across the biotechnology and pharmaceutical sector after 2017 led to a pause in deal-making.
Tax reform, particularly a lower levy on US companies’ overseas cash, may be the key to driving the return of M&A in 2018.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
